Deciphera Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Deciphera Pharmaceuticals Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Deciphera Pharmaceuticals presents a practical BD-screening case because its returned pipeline contains 22 records and the deal search returned 5 transaction records. The lead returned asset is Vimseltinib, associated with CSF-1R and Giant Cell Tumor of Tendon Sheath, Chronic graft-versus-host disease, Advanced cancer, at Approved. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Vimseltinib | Deciphera Pharmaceuticals, Inc. | Approved | Pipeline record: CSF-1R; Giant Cell Tumor of Tendon Sheath, Chronic graft-versus-host disease, Advanced cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) | Approved asset with CSF-1R exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | Ripretinib | Deciphera Pharmaceuticals, Inc. | Approved | Pipeline record: PDGFRα x c-Kit; Gastrointestinal Stromal Tumors, Melanoma, Systemic Mastocytosis. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe | Approved asset with PDGFRα x c-Kit exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | Tirabrutinib Hydrochloride | Deciphera Pharmaceuticals, Inc. | NDA/BLA | Pipeline record: BTK; Primary Central Nervous System Lymphoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Medison to market Deciphera's Qinlock for fourth-line treatment of gastrointestinal stromal tumor. | NDA/BLA asset with BTK exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | Vinseltinib | Deciphera Pharmaceuticals, Inc. | Phase 3 | Pipeline record: target not returned; Giant Cell Tumor of Tendon Sheath. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) | Phase 3 asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | Rebastinib Tosylate | Deciphera Pharmaceuticals, Inc. | Phase 2 | Pipeline record: Bcr-Abl T315I x HCK x Tie-2; Ovarian Cancer, Endometrial Carcinoma, Metastatic Solid Tumor. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe | Phase 2 asset with Bcr-Abl T315I x HCK x Tie-2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2024-04-29 | Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) | Completed | total_amount: 2400; disclosed: false |
| 2024-01-09 | GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe | Active | disclosed: false |
| 2020-11-06 | Medison to market Deciphera's Qinlock for fourth-line treatment of gastrointestinal stromal tumor. | Active | disclosed: false |
The most relevant returned precedent is: Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) (2024-04-29). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Deciphera Pharmaceuticals, Inc. - 2023 Annual report: Deciphera Pharmaceuticals, Inc. - 2023 Annual report Research and Development Expenses As of December 31, 2023, our principal sources of liquidity were cash, cash equivalents, and marketable securities of $352.9 million, which consisted of cash, money market funds, U.S. government securities, corporate debt securities, commercial paper, and certificates of deposit. The primary objectives of our investment activities are to preserve principal, provide liquidity, and maximize income without significantly increasing risk. Given the nature of these investments, we believe that the market for these instruments is not illiquid. The following table summarizes our sources and uses of cash and cash equivalents for each of the periods presented: Operating Activities During the year ended December 31
- Deciphera Pharmaceuticals, Inc. - 2023 Quarterly report: Deciphera Pharmaceuticals, Inc. - 2023 Quarterly report Research and Development Expenses As of June 30, 2023, our principal sources of liquidity were cash, cash equivalents, and marketable securities of $389.4 million, which consisted of cash, money market funds, U.S. government securities, commercial paper, corporate debt securities, and certificates of deposit. The primary objectives of our investment activities are to preserve principal, provide liquidity, and maximize income without significantly increasing risk. Given the nature of these investments, we believe that the market for these instruments is not illiquid. The following table summarizes our sources and uses of cash and cash equivalents for each of the periods presented: Six Months Ended June 30, Operating Activities During t
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Deciphera Pharmaceuticals is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Deciphera Pharmaceuticals merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Vimseltinib, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
